I read an online article today from Benzinga, a financial media company that empowers its readers with daily actionable market analysis and commentary.  It reported on a new ADHD drug that the FDA had just approved, called Cotempla XR-OTD, a methylphenidate extended release orally-disintegrating tablet for treating ADHD in kids aged 6-17.  According to BMO...Read More